Avelumab

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameAvelumab
Drug Alias Name阿维鲁单抗avelumabavelumabum阿维芦人单抗Bavencio +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsRespiratory papillomatosisPenile Squamous Cell CarcinomaSolid tumours +[60] 
Global Approved IndicationsCarcinoma, Merkel Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/03/23
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[54] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesJohannes Gutenberg-University MainzSamsung Medical CenterJules Bordet Institute +[20] 
Inactive CompaniesDana-Farber Cancer InstituteMerck Serono SaUniversity of Texas Southwestern Medical Center +[12] 
Active IndicationsRespiratory papillomatosisPenile Squamous Cell CarcinomaSolid tumours +[35] 
Inactive IndicationsMicrosatellite InstabilityGonadal DisordersTesticular Diseases +[25] 

Other Information

ATC CodeL01XC31
Related LinksWikipediaKEGG